enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Apixaban - Wikipedia

   en.wikipedia.org/wiki/Apixaban

   In the EU, apixaban is indicated for the prevention of venous thromboembolic events (VTE) in adults who have undergone elective hip or knee replacement surgery, the prevention of stroke and systemic embolism in adults with non-valvular atrial fibrillation (NVAF) with one or more risk factors, for the treatment of deep vein thrombosis (DVT) and ...

3. Direct factor Xa inhibitors - Wikipedia

   en.wikipedia.org/wiki/Direct_factor_Xa_inhibitors

   The monitoring of warfarin and keeping the international normalized ratio (INR) between 2.0 and 3.0, along with avoiding over and under treatment, has driven a search for an alternative. [3] [14] A naturally occurring inhibitor of factor Xa was reported in 1971 by Spellman et al. from the dog hookworm. [15]

4. ELIQUIS® (apixaban) Demonstrated Superiority In Reducing A ...

   www.aol.com/news/2012-12-08-eliquis-apixaban...

   AMPLIFY-EXT (Apixaban after the initial Management of PuLmonary embolIsm and deep vein thrombosis with First-line therapY-EXTended Treatment), a randomized, double-blind, multicenter trial ...

5. Discovery and development of direct Xa inhibitors - Wikipedia

   en.wikipedia.org/wiki/Discovery_and_development...

   Indication for Xa inhibitors is preventing deep vein thrombosis (DVT) which can lead to pulmonary embolism. It is also used to treat atrial fibrillation to lower the risk of stroke caused by a blood clot. Another indication is a prophylactic treatment for blood clotting due to atherosclerosis.

6. New Eliquis® (apixaban) Post-hoc Subanalysis of the ... - AOL

   www.aol.com/2013/08/31/new-eliquis-apixaban-post...

   New Eliquis® (apixaban) Post-hoc Subanalysis of the Phase III ARISTOTLE trial Demonstrated that within 30 Days of a Procedure, Stroke or Systemic Embolism and Major Bleeding were Uncommon Results ...

7. U.S. FDA Approves ELIQUIS® (apixaban) to Reduce the ... - AOL

   www.aol.com/news/2013-01-02-us-fda-approves...

   U.S. FDA Approves ELIQUIS ® (apixaban) to Reduce the Risk of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation ELIQUIS Demonstrated Superior Risk Reductions Versus ...